RP 7214
Alternative Names: RP-7214Latest Information Update: 28 Jan 2024
At a glance
- Originator Rhizen Pharmaceuticals
- Developer Incozen Therapeutics; Rhizen Pharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; COVID 2019 infections; Myelodysplastic syndromes
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(In volunteers) in USA (PO)
- 28 Jan 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in USA (PO)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Solid-tumours in Switzerland (PO)